DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow +17.4% ·
net new positions +7.7%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +7 | 103.65M | $2.65B | +11 | −5 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | — |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | — | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | — | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | — | 35.56M | $825.78M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 12.09M | -1.8% | $164.36M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 2 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 3 | State Street Global Advisors ✦ (passive) | 4.46M | -1.9% | $60.64M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 4.37M | +42.8% | $59.37M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 3.05M | +186.0% | $41.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 3.04M | +3.5% | $41.30M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 2.19M | +22.3% | $29.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.49M | +269.4% | $20.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Fisher Asset Management ✦ | 1.36M | +72.2% | $18.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.17M | +40.9% | $15.90M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | Renaissance Technologies ✦ | 173.10K | New | $2.35M | 0.0% | New | 1 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 102.40K | -43.1% | $1.39M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 78.22K | New | $1.06M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $2.35M | 0.0% |
| D. E. Shaw & Co. | $1.06M | 0.0% |
Exited
| Point72 Asset Management | $11.18M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 265 holders, 147.10M shares, $2.60B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.65K sh · $36,868
Director · 10.82K sh · $247,328
Director · 615 sh · $14,600
Officer · 2.77K sh · $64,882
Officer · 2.86K sh · $71,625
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology